Avid Pharmaceuticals, Philadelphia, says it has started a 200-patient Phase II clinical trial of 18(superscript)F-AV-45, "a molecular imaging compound, which has shown potential for early and accurate diagnosis of Alzheimer's disease in patients with symptoms of memory loss."
  The study will use "positron emission topography (PET) to allow visualization of the amyloid plaque deposits in the brain that are characteristic of Alzheimer's," making it easier to find and study Alzheimer's in the early stages.
  Last month, Avid hired away eResearch Technology Inc.'s chief financial officer, Richard Baron.